Abstract
Thrombospondin 1 (TSP1) is a matricellular protein that plays multiple roles in disease. Activation of the TGF-beta latent complex is a major regulatory node for controlling TGF-beta in homeostasis and disease. TSP1 can regulate the conversion of latent transforming growth factor-beta (TGF-beta) to its biologically active form in certain fibrotic diseases and cancers. We have developed peptide and small molecule antagonists that block TSP1 binding to the latent complex and inhibit TSP1-dependent activation of latent TGF-beta. These antagonists reduce TGF-beta activity and extracellular matrix production and fibrosis in multiple rodent models, particularly in fibrotic complications of diabetes. TGF-beta also plays a role in the osteolytic bone destruction characteristic of the plasma cell cancer, multiple myeloma. In both immune competent syngeneic mouse and human xenograft models, we showed that treatment with the TSP1-TGF-beta antagonist reduced disease burden, TGF-beta activity, and prevented bone destruction via a decrease in osteoclasts and an increase in osteoblasts. Current studies are examining the role of the TSP1-TGF-beta pathway in immune dysregulation in multiple myeloma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
